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Abstract: Stroke prevention with oral anticoagulants in patients with atrial ﬁbrillation
predisposes for bleeding. As a result, in select patient groups anticoagulation is withheld
because of a perceived unfavorable risk-beneﬁt ratio. Reasons for withholding anticoagula-
tion can vary greatly between clinicians, often leading to discussion in daily clinical practice
on the best approach. To guide clinical decision-making, we have reviewed available
evidence on the most frequently reported reasons for withholding anticoagulation: previous
bleeding, frailty and age, and an overall high bleeding risk.
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Introduction
Atrial ﬁbrillation (AF) is the most common cardiac arrhythmia and is associated
with heart failure, mortality, and ischemic stroke.1 Stroke prevention with antic-
oagulants predisposes AF patients for bleeding. As a result, in select patient groups
anticoagulation is withheld because of a perceived unfavorable risk-beneﬁt ratio.2–4
However, these choices cannot always be justiﬁed based on available evidence.
With an aging population, AF is becoming even more prevalent. Decision-
making concerning withholding or (re-)initiating anticoagulation is a growing
challenge for physicians.5 In parallel, AF patients are likely to have more comor-
bidities, and consequently are at higher risk of both stroke and bleeding.6,7
Increasingly common factors such as previous bleeding, frailty, and an overall
high bleeding risk are amongst the most frequently reported reasons for withholding
anticoagulation.2,8
In this review, evidence and gaps in the current knowledge of the beneﬁts and
risks of anticoagulation in AF are discussed, with a focus on high bleeding risk,
previous bleeding, and frailty.
Anticoagulation and high bleeding risk
Due to an increase in comorbidities, patients with AF will more often be at an
increased bleeding risk. Decision-making regarding anticoagulation can be particu-
larly challenging in these patients, especially when both stroke and bleeding risk are
high.2,9 Oral anticoagulants (OAC) used for stroke prevention in AF are vitamin K
antagonists (VKA), such as warfarin, or the non-vitamin K oral anticoagulants
(NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban.1 As described below,
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available evidence suggests the clinical beneﬁt of antic-
oagulation is higher than is often perceived.
In patients with a CHA2DS2-VASc stroke risk score of ≥2
(male) or ≥3 (female), anticoagulation is indicated by current
AF-guidelines, and it should be considered in patients with a
CHA2DS2-VASc of one (male) or two (female).
1,10 In the
GARFIELD-AF registry, 30% of the patients with
CHA2DS2-VASc ≥2 were not treated with oral anticoagula-
tion (OAC).2 The strongest predictors for withholding OAC
were concomitant antiplatelet therapy (odds ratio (OR) 15.0
[95% conﬁdence interval (CI) 14.1–15.8]) and a history of
bleeding (OR 2.5 [95% CI 2.2–3.0]).2 Compared to patients
on OAC, patients withheld from OAC had an increased risk
of all-cause mortality (5.3% vs 3.9%, p<0.001), ischemic
stroke or systemic embolism (1.6% vs 1.1%, p<0.001), but
a decreased risk of major bleeding (0.5% vs 0.8%, p<0.001).
Data from the NCDR PINNACLE, a prospective United
States-based registry focusing on quality-improvement,
showed an even higher proportion of 42% of the patients
with CHA2DS2-VASc ≥2 not treated with OAC.
11 In a multi-
variable model, lower CHA2DS2-VASc scores and higher
HAS-BLED scores were both associated with OAC non-
prescription.11,12 Similar observations were derived from
German insurance databases, where 40.5–48.7% of AF
patients were classiﬁed as “deﬁnite OAC under-use”.13
A Spanish, prospective, observational study in 1361 AF
patients with stable anticoagulation control with VKA
observed an annual cessation rate of 1.54%/year.14 In 80%
of them, OAC was stopped because of a major bleeding or
at the health care providers’ discretion. Cox regression
analysis showed that the occurrence of major bleeding,
heart failure, cancer, or renal impairment during follow-up
was all independently associated with early OAC cessation.
The authors conclude that many factors associated with
bleeding also predispose to OAC cessation. OAC cessation,
however, was associated with an increase in ischemic stroke
(Hazard Ratio (HR) 1.85 [95% CI 1.17–2.94]) and all-cause
mortality (HR 1.30 [95% CI 1.02–1.67]).
In a Dutch retrospective study, 45 out of 89 patients
(51%) with a history of AF and admitted with a ﬁrst
ischemic stroke were insufﬁciently anticoagulated prior
to their stroke.15 Taken into consideration the increased
occurrence of intracranial hemorrhage (ICH) as a result of
increased OAC use, strict adherence to AF-guidelines
could have prevented an estimated 20 out of 89 (22%)
ischemic strokes. In the Registry of the Canadian Stroke
Network, 90% of the 597 patients admitted with ischemic
stroke and known AF with increased stroke risk were not
therapeutically anticoagulated, or not anticoagulated at
all.16 These data demonstrate the perceived difﬁculties of
real-world anticoagulation management, and the impor-
tance of good anticoagulation control. Thus, it is of utmost
importance to know in which high-risk patient OAC can
still safely be prescribed.
To reduce AF-related events, more frequent monitoring
of high bleeding risk patients for presence of lower hemo-
globin levels and/or active (minor) bleeding, changes in
renal function, therapy adherence, and modiﬁable stroke
and/or bleeding risk factors, such as hypertension or alcohol
abuse, are likely to result in safer OAC use.1 The use of
accurate bleeding prediction models could diminish under-
or overtreatment with OAC in AF. Unfortunately, bleeding
prediction has been shown difﬁcult. Over the years, multi-
ple bleeding risk scores, such as the HAS-BLED, ATRIA,
GARFIELD-AF risk tool, or HEMORR2HAGES, have
been developed to help clinical decision-making.12,17–19
However, these risk scores have only moderate predictive
accuracy, especially in the elderly.20 Further complicating
matters is the fact that an increased bleeding risk is corre-
lated with an increased stroke risk, since strong bleeding
risk factors such as increasing age, vascular disease, or prior
stroke are the most important risk factors for ischemic
stroke.21–23
In an effort to improve the prediction of bleeding, the
ABC-bleeding risk score (Age, Biomarkers (high-sensitive
troponin T, GDF-15, and hemoglobin), Clinical history)
has been developed, which had a only slightly higher c-
statistic (0.68 [95% CI 0.66–0.70]) than the HAS-BLED
(0.61 [95% CI 0.59–0.63]) or the ORBIT score (0.65 [95%
CI 0.62–0.67]).24,25 Since the ABC-bleeding risk scores
require the assessment of GDF-15, a cytokine which is
upregulated in conditions of systemic inﬂammation or
oxidative stress, the score is currently not implemented
in daily clinical practice.26 An interesting aspect of GDF-
15 is that increased levels are not associated with an
increased risk of stroke, while it is strongly predictive of
bleeding.27 It will be interesting to see if GDF-15, and
perhaps other biomarkers, can guide clinicians with deci-
sion-making on anticoagulation (re-)initiation.
Management of patients with a high
bleeding risk
Several studies have focused on the question whether AF
patients with a high bleeding risk are better off when OAC
is withheld. However, based on current literature,
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anticoagulation is especially important in patients at a very
high stroke risk, regardless of HAS-BLED scores.
To assess the beneﬁt of OAC in AF, a net clinical beneﬁt
(NCB) using the method of Singer et al, is often calculated:
NCB= (ischemic strokeoff OAC – ischemic strokeon OAC) – 1.5 *
(intracranial hemorrhage rateon OAC – intracranial hemorrhage-
off OAC), in which the factor −1.5 is to compensate for the often
greater clinical impact of intracranial bleeding.28 A NCB >0
indicates that the beneﬁt of less ischemic stroke with OAC
outweighs the risk of ICH. A NCB for warfarin was calculated
for each CHA2DS2-VASc score in a large Swedish study of
182,678 patients with AF.29 For CHA2DS2-VASc 0 (ie, male
without risk factor), there was no NCB of warfarin treatment
(NCB 0.0 [95% CI −0.1–0.1]). In patients with CHA2DS2-
VASc ≥1, a positive NCBwas observed. The NCBwas highest
in the patients at the highest risk of stroke, regardless of HAS-
BLED scores. Similar results were seen in a large Danish study,
where VKA (with or without aspirin) vs no antithrombotic
treatment had a positive NCB in patients with a CHA2DS2-
VASc ≥2.30 The NCB with VKAwas greater in patients with
HAS-BLED ≥3 vs HAS-BLED <3 on VKA (NCB 2.21 [95%
CI 1.93–2.50] vs NCB 1.19 [95% CI 1.07–1.32]), and VKA +
aspirin (NCB 1.97 [95% CI 1.62–2.32] vs 0.81 [95% CI 0.56–
1.07]), respectively.30 High bleeding risk and high ischemic
stroke risk are positively correlated. In individuals with a high
bleeding risk, the risk reduction of ischemic stroke with OAC
supersedes the small increase in the risk of ICH.30 In a different
Danish study, the NCBwas calculated for warfarin, dabigatran,
rivaroxaban, and apixaban vs no anticoagulation.31 A positive
NCB was observed in both VKA or NOAC treated patients
with CHA2DS2-VASc ≥2. The NCB was even greater in the
subgroup of patients with HAS-BLED ≥3, irrespective of treat-
ment with VKA or NOAC.
However, there are some limitations to these studies.
Confounding by indication could have played an important
role in these analyses, as patients on different anticoagula-
tion strategies may differ in terms of stroke and bleeding
risk, possibly overestimating NCB counts.29,30,32
Furthermore, non-intracranial major or non-major clini-
cally relevant bleeding is not a part of the used NCB
formula, although they often play an important role in
clinical decision-making. However, despite these limita-
tions, the evidence for prescribing OAC despite high
bleeding risk remains strong.
The treatment of high-risk patients should not only focus
on the antithrombotic strategy, but also on reducing the risk
of bleeding. A ﬂowchart to help reduce bleeding risk is
shown in Table 1. Although many important bleeding risk
factors are non-modiﬁable, treatment should focus on cur-
rently known modiﬁable risk factors for bleeding, including
hypertension, labile international normalized ratio (INR),
concomitant drug-use, including over the counter drugs like
non-steroidal anti-inﬂammatory drugs (NSAID), and alcohol
abuse.1 A systolic blood pressure of >140 mmHg is asso-
ciated with an increased bleeding risk, and adequate blood
pressure control is therefore recommended to reduce bleed-
ing risk.1,33 In patients with labile INR, switching to a NOAC
should be considered.1 The concomitant use of antiplatelet
drugs, NSAIDs, and drugs inhibiting OAC metabolism can
strongly increase bleeding risk, and therefore their use should
be avoided if possible.34–39 Drugs affecting metabolism and
increasing bleeding risk in NOACs are primarily P-gp and
CYP3A4 inhibitors, and in VKA primarily CYP2C9 and
CYP3A4 inhibitors.40 Alcohol abuse (ie, ≥8 units/week)
shows conﬂicting results regarding bleeding risk.12,21,41
However, suspected heavy drinking is an important reason
for clinicians to withhold OAC.2 Since alcohol abuse is also
associated with an increased risk of stroke in AF patients and
medication non-adherence, addressing a patients’ alcohol
usage is nonetheless an important element of the manage-
ment of AF patients.21,33,42 However, there is no substantial
evidence to withhold OAC in alcohol abusers without sig-
niﬁcant hepatic impairment.
In patients at risk for gastrointestinal (GI) bleeding,
proton pump inhibitors (PPI) can be prescribed to reduce
bleeding risk. In a retrospective cohort study in Medicare
beneﬁciaries treated with either apixaban, rivaroxaban,
dabigatran, or warfarin, PPI co-therapy was associated
with a lower risk of hospitalization for upper GI-
bleeding.43,44 Only in patients categorized in the lowest
GI-bleeding risk decile, no protective effect of PPI ther-
apy was observed.44 Current guidelines recommend that
in patients with an elevated GI-bleeding risk PPI should
be considered, speciﬁcally in patients with a history of
GI-bleeding or ulcer, malignancy, or concomitant antipla-
telet therapy.9
Combined use of antiplatelet drugs and anticoagulants
strongly increases bleeding risk, and is a frequently
observed reason for withholding OAC.2,11,38,39 In compar-
ison to VKA monotherapy, single antiplatelet therapy in
addition to VKA or NOAC had a HR for major bleeding
of 1.82 (95% CI 1.76–1.89) and 1.28 (95% CI 1.13–1.44),
respectively.39 Concomitant dual antiplatelet therapy with
a NOAC or VKA was associated with a 1.2–3.9-fold and
2.4–5.4-fold higher risk of major bleeding, respectively.39
In a meta-analysis only including patients on low-dose
Dovepress Seelig et al
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aspirin from the pivotal NOAC trials, rates of stroke or
systemic embolism were lower with NOACs (HR 0.78
[95% CI 0.67–0.91]), in comparison to VKAs.45 The
rates of major bleeding were similar (HR 0.83 [95% CI
0.69–1.01]). The rates of ICH were lower (HR 0.38 [95%
CI 0.26–0.56]). The results from these studies suggest
NOACs may be both safer and more effective than
VKAs in patients on concomitant antiplatelet therapy.
There have only been head-to-head studies between
NOAC or VKA and concomitant antiplatelet use in
patients after a recent percutaneous coronary intervention
(PCI). The WOEST, PIONEER-AF PCI, RE-DUAL PCI,
and AUGUSTUS trials all showed less bleeding with dual
therapy (NOAC or VKAwith a P2Y12 inhibitor) compared
to triple therapy (dual therapy plus aspirin), with no sig-
niﬁcant difference in efﬁcacy.46–49 However, these indivi-
dual trials were not powered for the efﬁcacy endpoints. A
meta-analysis of the WOEST, PIONEER-AF PCI, and RE-
DUAL PCI trials suggests the incidence of ischemic
events with dual therapy vs triple therapy is equally
low.50 The current guidelines provide a good overview
and recommend an individualized approach of triple ther-
apy duration based on bleeding and atherothrombotic risk
with the aim to keep triple therapy duration as short as
possible.9 The optimal antithrombotic regimen beyond 1
year remains undeﬁned in these patients, but will also
importantly depend on risk factors for bleeding.
Although the far majority of AF patients with increased
stroke risk will beneﬁt from OAC, the risks can outweigh
the beneﬁts in some patients (e.g. patients with a non-
treatable cause of (recurrent) major bleeding).9 In these
patients, a left atrial appendage (LAA) occluding device or
surgical LAA occlusion may be considered according to
the current guidelines (class of recommendation IIb, level
of evidence C).1 The ASAP study included AF patients
with CHADS2≥1 and a contraindication for OAC (in 93%:
history or tendency of bleeding), in which a LAA occlud-
ing device (Watchman) was implanted.51 After implanta-
tion, patients received 6 months of clopidogrel or
ticlopidine, and lifelong aspirin. Ischemic stroke rate
(1.7%/year) was signiﬁcantly lower than expected based
on the predicted stroke risk of the cohort (7.3%/year). The
Table 1 Flowchart to help reduce bleeding risk in high-risk AF patients
1. Estimate beneﬁt of OAC
● Assess stroke risk (e.g. CHA2DS2-VASc)
● Identify known bleeding risk factors (e.g. anemia, age, previous bleeding, impaired renal function, etc.)
2. Treatment plan
● Treat modiﬁable risk factors
● Consider co-treatment with PPI, in:
○ History of GI-bleeding or ulcer
○ Malignancy
○ Concomitant antiplatelet therapy or NSAIDs
Risk factor Treatment option (s)
Hypertension Aim for <140 mmHg systolic blood pressure if tolerated
Heavy alcohol use (≥8 units/week) Discourage use of alcohol
Labile INR (Time in Therapeutic Range
(TTR) <60%)
● Consider switch to NOAC
● In case of VKA preference:
○ more frequent monitoring
○ switch to longer acting VKA
NSAIDs, strong P-gp inhibitors, or
antiplatelet therapy.
Avoid these medications if possible. Consider switch to an alternative treatment. In case of antiplatelet
therapy, consider switch from VKA to NOAC.
3. Monitoring plan
● Assess hemoglobin levels and renal function at least yearly
● Stimulate and monitor therapy adherence
● Actively ask for (minor) bleeding
Abbreviations: AF, atrial ﬁbrillation; OAC, oral anticoagulation; INR, international normalized ratio; NOAC, non-VKA oral anticoagulant; VKA, vitamin K Antagonist;
NSAID, non-steroidal anti-inﬂammatory drug; PPI, proton pump inhibitor.
Seelig et al Dovepress
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EWOLUTION trial was a nonrandomized, prospective
cohort study in which 1020 patients with a Watchman
device were enrolled.52 In this study, 72.2% of the patients
had a reported contraindication for OAC. The observed
ischemic stroke rate was 1.3 (95% CI 0.8–1.9) per 100
patient-years, which was 83% lower than predicted based
on historical data using the CHA2DS2-VASc score. In
patients with a previous major bleeding speciﬁcally, the
risk reduction was similar at 85% (observed risk: 1.2 [95%
CI 0.4–2.5]). Unfortunately, there are no randomized data
available on LAA occlusion in patients with a contraindi-
cation for OAC. However, based on available evidence,
LAA occlusion seems to be a safe and effective strategy in
patients with a contraindication for OAC.53
(Re-)initiation of anticoagulation
after bleeding
One of the most frequently reported reasons to withhold
anticoagulation is a history of bleeding, especially a his-
tory of ICH.2,3,14,54 Nevertheless, available data indicate a
beneﬁt of OAC resumption in patients with AF and a prior
major bleeding.
Recently, a meta-analysis was published comprising
5685 AF patients that experienced a major bleeding.55 In
comparison with the withholding of OAC after the index
bleeding, OAC restarters had a 46% relative risk (RR)
reduction of any thromboembolic event, and a 10.8%
absolute risk reduction for all-cause mortality.55
Restarting OAC was associated with an increased risk of
a recurrent major bleeding (OR 1.85), although no
increased risk of recurrence of the index bleeding event
(ie, ICH or GI-bleeding) was observed. NCB analysis,
including thromboembolic events, major bleeding, and
all-cause mortality, demonstrated that restarting OAC
was associated with a clinical advantage (NCB 0.11
[95% CI 0.09–0.14]).55 An important limitation, however,
is that all included studies were observational, and selec-
tion bias in these studies is possible.56 Furthermore, only
one study included patients with a history of “any major
bleeding”, whereas the other six studies solely focused on
either ICH or GI-bleeding. Therefore, these results should
be interpreted with caution.
A retrospective analysis of insurance data showed a
lower combined risk of ischemic stroke and all-cause
mortality with the resumption of warfarin (HR 0.76 [95%
CI 0.59–0.97]) or dabigatran (HR 0.66 [95% CI 0.44–
0.99]).57 In comparison to no re-initiation, warfarin
resumption had an increased risk of major bleeding (HR
1.56 [95% CI 1.10–2.22]), whereas dabigatran resumption
was not signiﬁcantly associated with major bleeding (HR
0.65 [95% CI 0.32–1.33]). The risk-beneﬁt ratio was,
therefore, higher for dabigatran than for warfarin. Careful
interpretation of these results is warranted, as differences
in time to resumption, dosing (75 mg dose was initiated in
9.6% of the dabigatran users), switching, and discontinua-
tion between warfarin or dabigatran treated patients could
have strongly inﬂuenced outcomes.56
In patients with a history of ICH and AF, an increasing
body of evidence shows the beneﬁts of OAC resumption.
However, there is substantial controversy regarding the
optimal time period for re-initiation.58–60 A pooled analysis
of the retrospective AF studies of Kuramatsu et al, and
Nielsen et al, showed that OAC restarters had a lower rate
of any thromboembolic event (HR 0.45 [95% CI 0.26–
0.78]), and that OAC resumption was not signiﬁcantly
associated with recurrent major bleeding (HR 1.65 [95%
CI 0.97–2.79]).55,61,62 In a model with any thromboembolic
event, major bleeding, and all-cause mortality, OAC
resumption after ICH resulted in a positive NCB.55 A
meta-analysis from eight studies with a retrospective design
comprised of 5306 patients hospitalized for anticoagula-
tion-associated ICH for any indication.63 The re-initiation
of OAC resulted in a lower risk of thromboembolic events
(RR 0.34 [95% CI 0.25–0.45]), without an increase in
recurrent ICH (RR 1.01 [95% CI 0.58–1.77]).63 Not only
a lower risk of thromboembolism has been observed, but
also an improvement in functional recovery of OAC
resumption in ICH survivors. A pooled analysis of three
prospective studies in 941 AF patients showed that antic-
oagulation resumption was associated with improved func-
tional recovery at 1-year post-ICH (OR 1.89 [95% CI 1.32–
2.70]).64 Although there is good evidence in favor of VKA
resumption from observational studies, data on NOAC
resumption after recent ICH are very limited.65,66 Data
from randomized controlled trials are not available.
APACHE-AF is an ongoing trial focusing on the safety
and efﬁcacy of full-dose apixaban vs antiplatelet drugs or
no antithrombotic therapy after recent ICH in AF.67
SoSTART is an ongoing trial with a similar design, but the
choice of OAC is left to the physician: dabigatran, rivarox-
aban, apixaban, edoxaban, warfarin, phenindione, or
acenocoumarol.68
Overall, (re-)initiation of OAC in AF patients after a
major bleeding seems to be beneﬁcial. However, it is
unclear what the optimal moment for (re-)starting OAC
Dovepress Seelig et al
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therapy is. In a retrospective assessment of insurance
data, 1329 patients with AF, a major GI-bleeding, and
an interruption of warfarin for 48 hrs were included.69
Warfarin restarters had a reduced risk of thromboembo-
lism (HR 0.71 [95% CI 0.54–0.93]) and all-cause
mortality (HR 0.67 [95% CI 0.56–0.81]), compared to
non-restarters. Both groups had a comparable risk of
recurrent GI-bleeding. Compared to restarting warfarin
after 30 days after GI-bleeding, an early restart within 7,
7–15, 15–21, or 21–30 days was not associated with a
decreased thromboembolic risk. In contrast, restarting
warfarin within 7, 7–15, or 15–21 days was associated
with a decreased all-cause mortality risk. Careful inter-
pretation of these results is warranted, as it is likely that
the different groups analyzed had different risks of
rebleeding and thromboembolism, given the high prob-
ability of selection bias. Moreover, in this study, restart-
ing warfarin within 7 days was associated with an
increased risk of recurrent GI-bleeding, compared to
restarting after 30 days.69 A retrospective study using
administrative and clinical databases showed that a
restart of warfarin, which was after a median of 4
days (95% CI 2–9), was not related with a recurrence
of GI-bleeding.70 However, when a restart within 1–7
days was compared with >7 days, the rate of recurrent
GI-bleeding was increased signiﬁcantly (12.4% and
6.23%, respectively).70 In a prospective study of 197
patients hospitalized for GI-bleeding, it was observed
that warfarin resumption after a median of 5 days
resulted in lower thromboembolic events (HR 0.12
[95% CI 0.006–0.81]), without increasing the risk of
GI-bleeding recurrence (HR 2.17 [95% CI 0.86–
6.67]).71,72 All-cause mortality within 90 days after
hospital discharge was similar between restarters and
non-restarters (HR 0.63 [95% CI 0.22–1.89]).
Therefore, it has previously been suggested that war-
farin resumption can be considered as early as 7–14
days after GI-bleeding.73 Since data are lacking on the
timing of NOAC resumption after GI-bleeding, the
authors advised to apply data for warfarin resumption
with caution, because of the faster therapeutic onset of
NOACs.73
In patients with ICH, “early resumption” (within 2
weeks) of OAC therapy in patients with a high risk of
thromboembolism, and “late resumption” (after 4 weeks)
in patients with a high risk of ICH, has been suggested.60
The most recent European Heart Rhythm Association
guidelines recommend that OAC may be restarted after
4–8 weeks after ICH, if the risk of thromboembolism is
high and the risk of recurrent ICH is low.9 In general, the
optimal timing of resumption after ICH is still largely
unknown, and is dependent on many factors. OAC should
not be restarted in patients with cerebral amyloid angio-
pathy, because of the high recurrent ICH risk.9 In other
situations, decision-making is more difﬁcult and should,
therefore, be decided in a multidisciplinary team.1,60 For
example, lobar bleeding, cerebral microbleeds, a non-trau-
matic origin, cerebral aneurysm, or lacunar infarcts are
associated with an increased risk of recurrent ICH, while
a deep cortical bleed has a relatively low recurrence risk.60
As data are limited, further research from preferably ran-
domized controlled trials is essential.
Anticoagulation and frailty
Frailty has been deﬁned as a syndrome of increased aging-
associated vulnerability, resulting in a compromised ability
to cope with stressors.74 With aging of the population, the
incidence of both frailty and AF increases drastically, and
is likely to result in an increased incidence of ischemic
stroke.9 It is however problematic that multiple reports
have shown a 50% lower prescription rate in frail AF
patients, compared to non-frail patients.75,76 In a question-
naire distributed amongst treating physicians of AF
patients from nursing homes in France, recurrent falls
(47%) and cognitive impairment (22%) were the most
common reasons for withholding OAC.4 Other studies
also found an (excessive) fall risk as an important reason
for OAC non-prescription.8,77 However, an increasing
body of evidence suggests that OAC should not be with-
held based on frailty solely.
A recent prospective study in hospitalized, elderly AF
patients in Spain showed that amongst patients with antic-
oagulation, the incidence of ischemic stroke (2.7% vs
3.2%, p=0.79) and major bleeding (7.5% vs 8.1%,
p=0.84) was similar between frail and non-frail patients
at 1-year follow-up, respectively.78
Fall risk is an important parameter of frailty. A his-
tory of falls or an increased fall risk is associated with
all-cause mortality, ischemic stroke, and bleeding.79–81
However, conﬂicting results have been published on the
risk of the most feared complication of anticoagulation in
patients with frailty: (traumatic) ICH.79–82 In a retrospec-
tive study in AF patients anticoagulated with warfarin,
the incidence rate per 100 patient-years of traumatic ICH
was 2.0 (95% CI 1.3–3.1)) in high fall risk AF patients,
and 0.34 (95% CI 0.27–0.45) in other patients.82 In a post
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hoc analysis of the ARISTOTLE trial, a history of fall(s)
was associated with an increased ICH risk (HR 1.96
[95% CI 1.06–3.61]).80 However, in the ENGAGE-AF
TIMI-48 trial and in the Loire Valley AF Project, the
presence or absence of fall risk or a history of fall(s), did
not increase the incidence of ICH.79,81 The reason for
these contradictory results is uncertain. Nevertheless,
using a Markov model, it was estimated that patients
with AF taking warfarin have to fall more than 295
times in 1 year for the risks of warfarin to outweigh its
beneﬁts.83 Also, for both edoxaban and apixaban the
relative safety and efﬁcacy proﬁle compared with war-
farin were consistent in high fall risk patients.80,81 Fall
risk alone should therefore not be a reason to withhold
anticoagulation.9
Dementia is another often cited reason for OAC non-
prescription in AF.4 However, like fall risk, dementia
should not be a general contraindication for OAC.9
Anticoagulation initiation and monitoring in dementia
can be challenging, as therapy adherence and a patients’
ability to make decisions are often suboptimal.9
Nonetheless, OAC treatment is correlated with lower
ischemic stroke and all-cause mortality rates in these
patients.84 Moreover, AF is linked to dementia and cogni-
tive decline, and OAC in AF has been associated with a
lower risk of dementia.85,86 Anticoagulation treatment is
therefore encouraged, but attention to therapy adherence is
especially important.
Conclusion
Anticoagulation management remains an important dis-
cussion topic, especially in an aging AF population with
progressively more comorbidities. Often, the perceived
unfavorable risk-beneﬁt ratio of anticoagulation is over-
estimated in these patients. Although a careful assess-
ment of risks and beneﬁts is warranted, the beneﬁts of
stroke prevention generally outweigh bleeding risk. This
holds true speciﬁcally in patients with commonly
reported reasons for anticoagulation withholding pre-
vious bleeding, frailty and age, and high bleeding risk
(Table 2). After major bleeding, the optimal timing of
anticoagulation resumption is largely unknown, and
often requires multidisciplinary assessment.
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Table 2 Summary of recommendations
Discussion
topic
Recommendations
High bleeding risk
High bleeding risk is often not a contraindication, as
stroke risk generally outweighs bleeding risk.
A detailed recommendation can be found in Table 1.
Recent major bleeding
Overall OAC resumption after major bleeding seems to be
beneﬁcial.
The optimal timing of resumption is not extensively
researched.
GI-bleeding Resumption of OAC is generally recommended.
Resumption of OAC can be considered as early as
within 7–14 days after GI-bleeding.
ICH Resumption of OAC is often beneﬁcial, but should
be decided in a multidisciplinary team as the beneﬁts
and risks are dependent on many factors.
The optimal timing of resumption is unknown. If
OAC is resumed, restarting after 4 weeks is deemed
safe.
Frailty and age
Overall Frailty and age are no general contraindications for
OAC.
High fall risk A high risk of falls, or a history of falls, are no general
contraindications for OAC.
Cognitive
decline
OAC should not generally be withheld in patients
with cognitive decline. Feasibility of OAC treatment
in terms of medication adherence should always be
checked and monitored.
Abbreviations: OAC, oral anticoagulation; GI, gastrointestinal; ICH, intracranial
hemorrhage.
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